|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McIntyre A and Ganti AK: Lung cancer-A
global perspective. J Surg Oncol. 115:550–554. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kerr KM, Galler JS, Hagen JA, Laird PW and
Laird-Offringa IA: The role of DNA methylation in the development
and progression of lung adenocarcinoma. Dis Markers. 23:5–30. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brzeziańska E, Dutkowska A and Antczak A:
The significance of epigenetic alterations in lung carcinogenesis.
Mol Biol Rep. 40:309–325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Green DR and Kroemer G: Cytoplasmic
functions of the tumour suppressor p53. Nature. 458:1127–1130.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gibbons DL, Byers LA and Kurie JM:
Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 12:3–13.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saldaña-Meyer R and Recillas-Targa F:
Transcriptional and epigenetic regulation of the p53 tumor
suppressor gene. Epigenetics. 6:1068–1077. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mahmoudi S, Henriksson S, Corcoran M,
Méndez-Vidal C, Wiman KG and Farnebo M: Wrap53, a natural p53
antisense transcript required for p53 induction upon DNA damage.
Mol Cell. 33:462–471. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bug M and Dobbelstein M: Anthracyclines
induce the accumulation of mutant p53 through E2F1-dependent and
-independent mechanism. Oncogene. 30:3612–3624. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan JM, Li XD, Liu ZY, Hou GQ, Kang JH,
Huang DY and Du SX: Cisplatin induces apoptosis via upregulating
Wrap53 in U-2OS osteosarcoma cells. Asian Pac J Cancer Prev.
12:3465–3469. 2011.PubMed/NCBI
|
|
11
|
Pouladi N, Kouhsari SM, Feizi MH, Gavgani
RR and Azarfam P: Overlapping region of p53/wrap53 transcripts:
Mutational analysis and sequence similarity with microRNA-4732-5p.
Asian Pac J Cancer Prev. 14:3503–3507. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mahmoudi S, Henriksson S, Farnebo L,
Roberg K and Farnebo M: WRAP53 promotes cancer cell survival and is
a potential target for cancer therapy. Cell Death Dis. 2:e1142011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H, Wang DW, Adell G and Sun XF:
WRAP53 is an independent prognostic factor in rectal cancer-a study
of Swedish clinical trial of preoperative radiotherapy in rectal
cancer patients. BMC Cancer. 12:2942012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rao X and Huang D, Sui X, Liu G, Song X,
Xie J and Huang D: Overexpression of WRAP53 is associated with
development and progression of esophageal squamous cell carcinoma.
PLoS One. 9:e916702014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan XS, Cao LX, Hu YJ, Bao FC, Wang ZT,
Cao JL, Yuan P, Lv W and Hu J: Clinical, cellular, and
bioinformatic analyses reveal involvement of WRAP53 overexpression
in carcinogenesis of lung adenocarcinoma. Tumor Biol.
39:10104283176943092017. View Article : Google Scholar
|
|
16
|
Lee EB, Jin G, Lee SY, Park JY, Kim MJ,
Choi JE, Jeon HS, Cha SI, Cho S, Kim CH, et al: TP53 mutations in
Korean patients with non-small cell lung cancer. J Korean Med Sci.
25:698–705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Swiatkowska A, Zydowicz P, Sroka J and
Ciesiołka J: The role of the 5′ terminal region of p53 mRNA in the
p53 gene expression. Acta Biochim Pol. 63:645–651. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alonso S, Izarirre N, López S,
Smith-Zubiaga I, Hervella M, Boyano MD, Arroyo-Berdugo Y,
Gardeazabal J, Díaz-Ramón JL, Sánchez Díez A, et al: The diversity
profile of TP53 is influenced by positive selection on the
immediately upstream locus WDR79. Hum Hered. 69:34–44. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nie L, Wu HJ, Hsu JM, Chang SS, Labaff AM,
Li CW, Wang Y, Hsu JL and Hung MC: Long non-coding RNAs: Versatile
master regulators of gene expression and crucial players in cancer.
Am J Transl Res. 4:127–150. 2012.PubMed/NCBI
|
|
20
|
Su WY, Xing H and Fang JY: Natural
antisense transcripts regulate gene expression in an epigenetic
manner. Biochem Biophys Res Commun. 396:177–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kanai Y: Alterations of DNA methylation
and clinicopathological diversity of human cancers. Pathol Int.
58:544–558. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu Q and Ni X: ROS-mediated DNA
methylation pattern alterations in carcinogenesis. Curr Drug
Targets. 16:13–19. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin RK and Wang YC: Dysregulated
transcriptional and post-translational control of DNA
methyltransferases in cancer. Cell Biosci. 4:462014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jin T, Hao J and Fan D: Nicotine induces
aberrant hypermethylation of tumor suppressor genes in pancreatic
epithelial ductal cells. Biochem Biophys Res Commun. 499:934–940.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin RK, Wu CY, Chang JW, Juan LJ, Hsu HS,
Chen CY, Lu YY, Tang YA, Yang YC, Yang PC and Wang YC:
Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1
overexpression in lung cancer. Cancer Res. 70:5807–5817. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang YA, Tsai YT, Lin RK, Hsu HS, Chen CY
and Wang YC: Dysregulation of p53 and RB transcriptional control
leads to overexperssion of DNA methyltransferase in lung cancer. J
Cancer Res Pract. 1:14–27. 2014. View Article : Google Scholar
|
|
27
|
Yue X, Zhao Y, Xu Y, Zheng M, Feng Z and
Hu W: Mutant p53 in cancer: Accumulation, gain-of-function, and
therapy. J Mol Biol. 429:1595–1606. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yeang CH, McComick F and Levine A:
Combinatorial patterns of somatic gene mutations in cancer. FASEB
J. 22:2605–2622. 2008. View Article : Google Scholar : PubMed/NCBI
|
